IQVIA vs Saama (2026)
IQVIA is a research services and health data company that now sells AI agents through IQVIA.ai, a catalog built with NVIDIA in March 2026. Its agents cover literature review, deep research on its own Med-R1 model, field force and market insight work, and they draw on IQVIA's own data such as MIDAS. In October 2026 it added Life Science Models that forecast trial outcomes. A sponsor typically buys the agents alongside IQVIA's data and the people who run its studies. Saama is a software company whose platform works on the sponsor's own trial data. Smart Data Quality finds discrepancies and drafts queries for a reviewer to approve. BRAIN SDTM maps raw data to the CDISC SDTM submission standard, and Clinical AI Agents, launched in September 2025, run from study start to submission. Pfizer has used its data review automation since 2020. The choice comes down to who does the work. With IQVIA, the data and often the people doing the work come with the AI. With Saama, the sponsor keeps its data and its team and buys the software. A sponsor that wants one partner for data, services and agents fits IQVIA. A sponsor equipping its own data management and biometrics team fits Saama.
- IQVIA.ai's agents draw on IQVIA's own data sources, including MIDAS market data and real world cohorts.
- The Med-R1 Deep Research Agent runs on IQVIA's own Med-R1 8B medical reasoning model.
- Agents can deploy in IQVIA's technology stack or the client's.
- IQVIA Life Science Models forecast trial outcomes, with 85 percent of predictions on target or clinically close across 50 trials.
- IQVIA's annual report places its global data centers inside an annual SOC 2 Type II audit.
- Smart Data Quality drafts data queries for a reviewer to approve, and Saama credits it with more than 20,000 hours saved.
- Its SDTM mapping, now sold as BRAIN SDTM, shows a confidence score for each suggested mapping.
- Data Hub connects to more than 40 data sources, and the platform runs on AWS in the United States.
- Pfizer has used its data review automation since 2020, starting with its COVID-19 vaccine trial.
- Saama states it acts as a business associate where it handles protected health information.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. IQVIA and Saama are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
IQVIA
-
Model / architecture
IQVIA launched IQVIA Life Science Models, a suite of purpose built AI models on NVIDIA Nemotron and AWS infrastructure.
Source -
Product / capability
IQVIA launched Predictive Clinical Development, a suite covering site selection and study design, an automated start up path it calls Push Button Start-Up, and real time data cleaning aimed at shortening the gap to database lock.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
IQVIA sells research services, health data and technology to life sciences companies, and its IQVIA.ai catalog adds AI agents for literature review, deep research, commercial planning, field force and cohort work. The agents run on IQVIA's own data and its Med-R1 model with NVIDIA's software stack, and 19 of the top 20 pharmaceutical companies have begun using them, by IQVIA's count. Life Science Models, launched in October 2026, predict trial outcomes. IQVIA does not publish what each agent may do without a person, whether customer feedback trains shared models, or a price.
Source: AI Health Index, October 2026
Saama sells clinical data software to pharmaceutical and biotech sponsors and contract research organizations: Smart Data Quality for data review and queries, BRAIN SDTM for mapping data to the CDISC submission standard, Data Hub for ingestion, and Clinical AI Agents across the trial. A person approves each model output, and Pfizer has used its data review since 2020. The platform runs on AWS in the United States, and Saama states its business associate role in its privacy notice. Its outcome figures carry no method, its security program is aligned to ISO 27001 without certification, and it publishes no price.
Source: AI Health Index, October 2026
Questions buyers ask
How does IQVIA compare to Saama?
IQVIA and Saama both sell AI to drug sponsors for clinical development, with different business models behind it. IQVIA offers a catalog of agents through IQVIA.ai, built on its own health data and Med-R1 model and usually bought alongside its research services. Saama sells software that runs on the sponsor's own data, for data review, SDTM mapping and agents from study start to submission.
One partner for data, services and AI points to IQVIA, while a sponsor equipping its own team points to Saama. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 25, 2026. No vendor pays for placement.
How much do IQVIA and Saama cost?
Neither IQVIA nor Saama publishes a price. IQVIA's agents usually come inside enterprise agreements that bundle data, services and clinical research, and its catalog shows availability without terms. Saama sells platform licenses and services, and its site does not say whether a purchase is priced per study, per user or per project. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 25, 2026. No vendor pays for placement.
Do IQVIA's and Saama's AI agents act on their own?
Saama says a person must approve every model output: queries go to a reviewer, each SDTM mapping carries a confidence score to accept or reject, and generated data checks are tested and approved before use. It also describes its agents as capable of extensive independent execution, without publishing their limits. IQVIA says its agents keep experts in the loop while defining agentic AI as acting without constant supervision, and it does not publish what any agent may do unattended. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 25, 2026. No vendor pays for placement.
How do IQVIA and Saama handle security and sponsor data?
IQVIA's annual report says its global data centers sit inside an annual SOC 2 Type II audit, without saying whether IQVIA.ai is in scope, and IQVIA states no business associate role for the agents. Saama runs its platform on AWS in the United States, states a business associate role where it handles protected health information, and aligns its security program to ISO 27001 without holding the certificate.
Saama trains some models on a customer's prior study data and does not say whether that learning crosses sponsors. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 25, 2026. No vendor pays for placement.
What evidence supports IQVIA's and Saama's AI?
IQVIA reports more than 200 AI publications, benchmark scores for its Med-R1 model, and a first evaluation of its Life Science Models across 50 trials and 270 endpoints, with 85 percent of predictions on target or clinically close. Saama names Pfizer as a customer since 2020 and reports figures such as more than 20,000 hours saved with Smart Data Quality, none with a method. Neither has published an outcome study of its agents. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 25, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
IQVIA is based in Research Triangle Park, North Carolina. Saama is based in Campbell, California, and is backed by a growth investment led by Carlyle. Neither claims FDA clearance for its AI, which supports trial operations and submissions rather than patient care. Saama says its program is aligned to 21 CFR Part 11 and ICH E6, while IQVIA publishes no position on how its agents sit inside validated systems. Neither publishes a price or a SOC 2 report a buyer can read.
IQVIA acts toward sponsor data as service provider, data holder and software vendor and does not say which role governs each agent. Saama has not said whether what its models learn from one sponsor's data reaches models serving another, or what its agents may do without approval.